The Role of Nasal Corticosteroids in the Treatment of Rhinitis - 11/08/11

Doi : 10.1016/j.iac.2011.05.004

Eli O. Meltzer, MD
Allergy & Asthma Medical Group & Research Center, 5776 Ruffin Road, San Diego, CA 92123, USA

Résumé

Intranasal corticosteroids (INSs) are the first choice for rhinitis pharmacotherapy. This preference is because of their broad range of actions that result in reductions of proinflammatory mediators, cytokines, and cells. Over the past 30 years, INSs have been modified to improve their pharmacodynamic, pharmacokinetic, and delivery system properties, with attention to improving characteristics such as receptor binding affinity, lipophilicity, low systemic bioavailability, and patient preference. Clinically, they have been shown to be the most effective class of nasal medications for treating allergic rhinitis and nonallergic rhinopathy, with no clear evidence that any specific INS is superior to others.

Le texte complet de cet article est disponible en PDF.

Keywords : Allergic rhinitis, Vasomotor rhinitis, Nonallergic rhinopathy, Intranasal corticosteroids, Corticosteroid pharmacology, Rhinitis treatment

Plan

Disclosure Statement: Grant/Research Support: Alcon, Alexza, Amgen, Antigen Labs, Apotex, Astellas, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MAP, MEDA, Merck, Novartis, Proctor & Gamble, Schering-Plough, Teva, UCB; Consultant/Speaker: Alcon, Alexza Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Capnia, Dainippon Sumitomo Pharma, Dey, GlaxoSmithKline, ISTA, Johnson & Johnson, Kalypsys, MAP Pharmaceuticals, Meda, Merck, National Jewish Health, Rady Children’s Hospital, Sandoz, sanofi-aventis, Schering-Plough, Sepracor, SRxA, Teva, VentiRx, Wockhardt, Wyeth; Major Stock Shareholder: None; Other Financial or Material Support and Gifts: None.